EFFICACY AND SAFETY OF TICAGRELOR IN PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME AFTER CORONARY ARTERY BYPASS GRAFTING
https://doi.org/10.29001/2073-8552-2016-31-1-31-35
Abstract
In this study, we attempted to demonstrate prospects of proper dual antiplatelet drug therapy in acute coronary syndrome (ACS) without STsegment elevation in patients who required surgical coronary intervention during primary hospitalization. The existing problems and their possible solutions were taken into account according to the state of the art; the interests of both a surgeon and a cardiologist were identified in a way they presented no harm to a patient. Objective of the study was to compare the efficacy and the safety of therapy with study drug, Ticagrelor, and with Clopidogrel in patients with ACS without STsegment elevation in the presence of continuing therapy with Aspirin when Ticagrelor and Clopidogrel were cancelled before surgical intervention. This study included 83 patients with verified diagnosis and predicted development of unfavorable cardiovascular events in the nearest 30 days. Patients were randomized into 2 groups by envelope method. Group 1 was administered with Ticagrelor; group 2 was administered with Clopidogrel; all patients additionally received Aspirin. All patients underwent surgical treatment: coronary artery bypass grafting (CABG). In this study, we evaluated the effects of stopping drug therapy with Ticagrelor 1 to 3 days before CABG and Clopidogrel 5 days before surgery. Both advantages and disadvantages of these drugs were taken into account in regard to unfavorable coronary events both in both preoperative and postoperative periods. The work demonstrated the potential problems associated with greater blood loss during surgical intervention and after the use of study drug.
About the Authors
I. M. Skurikhin
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
E. V. Vyshlov
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
Yu. Yu. Vechersky
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
V. V. Zatolokin
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
References
1. Скурихин И.М., Вечерский Ю.Ю., Вышлов В.В. и др. Совре¬менное состояние и проблемы хирургического лечения пациентов с острым коронарным синдромом без элевации сегмента ST // Сибирский медицинский журнал (Томск). – 2014. – Т. 29, №3. – С. 12–18.
2. Вечерский Ю.Ю., Затолокин В.В., Андреев С.Л. и др. Техни¬ческие аспекты аутоартериального коронарного шунтиро¬вания // Сибирский медицинский журнал (Томск). – 2015. – Т. 30, № 2. – С. 65–69.
3. Hochtl T., Sinnaeve P.R., Adriaenssens T. et al. Oral antiplatelet therapy in acute coronary syndromes: update 2012 // Eur. Heart J. Acute Cardiovasc. Care. – 2012. – No. 1. – P. 79–86.
4. Steg P.G., James S.K., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST¬segment elevation // Eur. Heart J. – 2012. – Vol. 33. – P. 2569–2619.
5. Hamm C.W., Bassand J.P., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST¬segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST¬segment elevation of the European Society of Cardiology (ESC) // Eur. Heart J. – 2011. – Vol. 32. – P. 2999–3054.
6. Husted S., van Giezen J.J. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist // Cardiovasc. Ther. – 2009. – Vol. 27. – P. 259–274.
7. Siller¬Matula J.M., Trenk D., Krahenbuhl S. et al. Clinical implications of drug¬drug interactions with P2Y12 receptor inhibitors // J. Thromb. Haemost. – 2014. – Vol. 12. – P. 2–13.
8. James S., Akerblom A., Cannon C.P. et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial // Am. Heart J. – 2009. – Vol. 157. – P. 599–605.
9. Held C., Asenblad N., Bassand J.P. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial // J. Am. Coll. Cardiol. – 2011. – Vol. 57. – P. 672–684.
10. Schotola H., Brauer A., Meyer K. et al. Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug // Eur. J. Cardiothorac. Surg. – 2014. – Vol. 46. – P. 198–205.
11. Hansson E.C., Rexius H., Dellborg M. et al. Coronary artery bypass grafting¬related bleeding complications in real¬life acute coronary syndrome patients treated with clopidogrel or ticagrelor // Eur. J. Cardiothorac. Surg. – 2014. – Vol. 46. – P. 699–705.
Review
For citations:
Skurikhin I.M., Vyshlov E.V., Vechersky Yu.Yu., Zatolokin V.V. EFFICACY AND SAFETY OF TICAGRELOR IN PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME AFTER CORONARY ARTERY BYPASS GRAFTING. Siberian Journal of Clinical and Experimental Medicine. 2016;31(1):31-35. (In Russ.) https://doi.org/10.29001/2073-8552-2016-31-1-31-35
Views:
277
.png)
Email this article 